Allakos Secures $100 Million In Series B Financing
13 déc. 2017 09h00 HE
|
Allakos
Proceeds will support advancement of AK002 in five disease areas Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease SAN CARLOS,...
Allakos Announces Additions to Senior Leadership Team
15 août 2017 10h01 HE
|
Allakos
Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., Aug. ...